Rubitecan
| File:Rubitecan.png | |
| Gene therapy | |
|---|---|
| Clinical data | |
| Routes of administration | Oral |
| Physiological data | |
| Legal status | |
| Pharmacokinetic data | |
| Identifiers | |
| CAS Number | |
| PubChem Template:Abbreviation | |
| Chemical and physical data | |
| Formula | C20H15N3O6 |
| Molar mass | 393.349 g/mol |
|
WikiDoc Resources for Rubitecan |
|
Articles |
|---|
|
Most recent articles on Rubitecan |
|
Media |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Rubitecan at Clinical Trials.gov Clinical Trials on Rubitecan at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Rubitecan
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Rubitecan Discussion groups on Rubitecan Directions to Hospitals Treating Rubitecan Risk calculators and risk factors for Rubitecan
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Rubitecan |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Overview
Rubitecan (INN, marketing name Orathecin) is an oral topoisomerase inhibitor, developed by Supergen.
History
On January 27, 2004, Supergen announced that it has completed the submission of an NDA for rubitecan to the US FDA, [1] and was accepted for filing on March 2004.[2]
On January 2005, Supergen withdrew the NDA for rubitecan, based on feedback indicating that the current data package would not be sufficient to gain US approval,[3] and on January 2006, the Marketing Authorization Application (MAA) filed with the European Medicines Agency (EMA) was also withdrawn.[4]
References
- ↑ "Drugs.com, SuperGen completes submission of New Drug Application (NDA) for Orathecin as an oral treatment for pancreatic cancer". Retrieved 2008-03-25.
- ↑ "Drugs.com, SuperGen's New Drug Application for Orathecin (rubitecan) capsules accepted by FDA for filing". Retrieved 2008-03-25.
- ↑ "Drugs.com, SuperGen Announces Withdrawal of Orathecin NDA". Retrieved 2008-03-25.
- ↑ "Press release from the EMEA website regarding withdrawal of Orathecin MAA" (PDF). Retrieved 2008-03-25.
- Articles with short description
- Pages with broken file links
- Infobox-drug molecular-weight unexpected-character
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs missing an ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Cancer treatments
- Chemotherapeutic agents